REPL Company Profile and Key Details

Q: Who are the executives of REPL?

Ms. Tanya N. Lewis M.S.Chief Devel. Operations OfficerDr. Pamela Esposito Ph.D.Chief Bus. OfficerMr. Sushil Patel Ph.D.Chief Commercial OfficerDr. Kostas Xynos M.B.A., M.D., Ph.D.Chief Medical OfficerAndrew SchwendenmanChief Accounting OfficerMr. Christopher SarchiChief Commercial OfficerMr. Philip Astley-Sparke FSAChief Executive Officer & DirectorDr. Sushil Patel Ph.D.Chief Strategy OfficerDr. Robert Coffin Ph.D.Founder, Pres, Chief R&D Officer and DirectorMr. Andrew SchwendenmanChief Accounting Officer & TreasurerDr. Konstantinos Xynos M.B.A., M.D., Ph.D.Chief Medical OfficerDr. Colin A. Love Ph.D.Chief Operating OfficerMr. Philip Astley-Sparke F.S.A., FSAChief Executive Officer, Interim Chief Financial Officer & DirectorMs. Jean M. FranchiChief Financial Officer, Treasurer, Sec. & Compliance Officer

NASDAQ : REPL

Replimune Group

$11.20

5.79+107.02%

At Close 4:00 PM

61.53

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Replimune Group, Inc. (REPL) stock surged +107.02%, trading at $11.20 on NASDAQ, up from the previous close of $5.41. The stock opened at $11.38, fluctuating between $9.44 and $12.49 in the recent session.

Stock Snapshot

5.41

Prev. Close

940.4M

Market Cap

9.44

Day Low

-3.31

P/E Ratio

-3.38

EPS (TTM)

-2.64

Cash Flow per Share

11.38

Open

83.96M

Number of Shares

12.4899

Day High

82.02%

Free Float in %

6.33

Book Value

33.34M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 31, 2026	11.38	12.50	9.43	11.20	33.44M
Jul 29, 2026	5.25	5.57	4.76	5.41	14.27M
Jul 28, 2026	6.61	6.62	5.14	5.35	23.98M
Jul 27, 2026	8.69	9.15	7.37	8.63	8.45M
Jul 24, 2026	10.30	10.38	9.65	9.70	3.27M
Jul 23, 2026	10.71	10.98	10.27	10.46	3.79M
Jul 22, 2026	10.97	11.24	10.69	10.75	1.62M
Jul 21, 2026	10.73	11.18	10.38	11.00	4.07M
Jul 20, 2026	10.28	10.72	9.96	10.51	4.29M
Jul 17, 2026	9.37	10.31	9.31	10.23	3.71M
Jul 16, 2026	9.47	9.60	8.91	9.52	3.56M
Jul 15, 2026	9.72	9.90	9.33	9.68	1.58M
Jul 14, 2026	9.94	10.40	9.74	9.87	3.3M
Jul 13, 2026	10.91	10.91	9.79	9.94	2.83M
Jul 10, 2026	11.10	11.11	10.46	10.99	2.3M
Jul 09, 2026	11.18	11.32	10.90	11.11	2.74M
Jul 08, 2026	11.48	11.68	10.84	11.12	3.27M
Jul 07, 2026	11.61	11.85	11.24	11.51	2.09M
Jul 06, 2026	11.53	11.75	11.33	11.47	1.63M
Jul 02, 2026	11.24	11.95	11.09	11.58	2.84M

Contact Details

Woburn, MA 01801

United States

https://www.replimune.com 781 222 9600

About Company

Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.

Stock Peers

ARGX

-18.76-2.15%

argenx SE$853.82 REGN

24.29+3.29%

Regeneron Pharmaceuticals, Inc.$762.63 UTHR

-8.11-1.54%

United Therapeutics Corporation$517.71 VRTX

-4.6-0.95%

Vertex Pharmaceuticals Incorporated$477.10 MDGL

-25.79-5.23%

Madrigal Pharmaceuticals, Inc.$467.32 KRYS

-25.73-7.01%

Krystal Biotech, Inc.$341.12 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ONC

-6.07-1.88%

BeOne Medicines AG$316.01 PRAX

0.08+0.03%

Praxis Precision Medicines, Inc.$307.83 LGND

-8.75-2.95%

Ligand Pharmaceuticals Incorporated$287.54

Frequently Asked Questions

What is the current Replimune Group, Inc. (REPL) stock price?

Replimune Group, Inc. (NASDAQ: REPL) stock price is $11.20 in the last trading session. During the trading session, REPL stock reached the peak price of $12.49 while $9.44 was the lowest point it dropped to. The percentage change in REPL stock occurred in the recent session was 107.02% while the dollar amount for the price change in REPL stock was $5.79.

REPL's industry and sector of operation?

The NASDAQ listed REPL is part of Biotechnology industry that operates in the broader Healthcare sector. Replimune Group, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of REPL?

Ms. Tanya N. Lewis M.S.
Chief Devel. Operations Officer
Dr. Pamela Esposito Ph.D.
Chief Bus. Officer
Mr. Sushil Patel Ph.D.
Chief Commercial Officer
Dr. Kostas Xynos M.B.A., M.D., Ph.D.
Chief Medical Officer
Andrew Schwendenman
Chief Accounting Officer
Mr. Christopher Sarchi
Chief Commercial Officer
Mr. Philip Astley-Sparke FSA
Chief Executive Officer & Director
Dr. Sushil Patel Ph.D.
Chief Strategy Officer
Dr. Robert Coffin Ph.D.
Founder, Pres, Chief R&D Officer and Director
Mr. Andrew Schwendenman
Chief Accounting Officer & Treasurer
Dr. Konstantinos Xynos M.B.A., M.D., Ph.D.
Chief Medical Officer
Dr. Colin A. Love Ph.D.
Chief Operating Officer
Mr. Philip Astley-Sparke F.S.A., FSA
Chief Executive Officer, Interim Chief Financial Officer & Director
Ms. Jean M. Franchi
Chief Financial Officer, Treasurer, Sec. & Compliance Officer

How REPL did perform over past 52-week?

REPL's closing price is 646.67% higher than its 52-week low of $1.50 where as its distance from 52-week high of $12.50 is -10.4%.

How many employees does REPL have?

Number of REPL employees currently stands at 465.

Link for REPL official website?

Official Website of REPL is: https://www.replimune.com

How do I contact REPL?

REPL could be contacted at phone 781 222 9600 and can also be accessed through its website. REPL operates from 500 Unicorn Park Drive, Woburn, MA 01801, United States.

How many shares of REPL are traded daily?

REPL stock volume for the day was 33.34M shares. The average number of REPL shares traded daily for last 3 months was 6.33M.

What is the market cap of REPL currently?

The market value of REPL currently stands at $940.40M with its latest stock price at $11.20 and 83.96M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	465
Beta	0.87
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	March
Sector	Healthcare
Industry	Biotechnology

Employees	465
Beta	0.87
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	March
Sector	Healthcare
Industry	Biotechnology

REPL Company Profile and Key Details

Replimune Group

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Financial & Profitability Overview

Quarterly Financial Highlights

Technical Performance

Shareholding & Insider Activity

Earnings & Analyst Outlook

Dividend & Fair Value

Valuation Metrics

Company Overview

Key Takeaways

Price Forecast & Outlook